Mylan N V Quick Ratio (MYL) starting from the third quarter 2020 to third quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Mylan N v   (NASDAQ: MYL)

Mylan N V 's Quick Ratio

MYL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Mylan N V 's Cash & cash equivalent grew by 105.35 % in the Q3 2020 sequentially, faster than Current Liabilities, this led to improvement in Mylan N V 's Quick Ratio to 0.09, Quick Ratio remained below Mylan N v average.

Within Major Pharmaceutical Preparations industry 477 other companies have achieved higher Quick Ratio than Mylan N V in third quarter 2020. While Quick Ratio total ranking has improved so far during the Q3 2020 to 4416, from total ranking in the second quarter 2020 at 4631.

Explain Quick Ratio?
How much Cash & cash equivalents MYL´s has?
What are MYL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MYL Quick Ratio (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3
Y / Y Current Liabilities Change 56.63 % 52.82 % 25.75 % 21.72 % -10.36 %
Y / Y Cash & cash equivalent Change 85.15 % 53 % 149.09 % 32.59 % -20.1 %
Quick Ratio MRQ 0.09 0.05 0.11 0.09 0.08
MYL's Total Ranking # 4416 # 4631 # 4313 # 3801 # 4473
Seq. Current Liabilities Change 4.36 % 33.34 % -6.37 % 20.22 % 1.82 %
Seq. Cash & cash equivalent Change 105.35 % -43.47 % 11.23 % 43.38 % 69.69 %



Quick Ratio third quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 478
Healthcare Sector # 963
Overall Market # 4416


Quick Ratio Statistics
High Average Low
4.92 0.83 0.04
(Dec. 31. 2004)   IV. Quarter




Financial Statements
Mylan N V 's Current Liabilities $ 7,275 Millions Visit MYL's Balance sheet
Mylan N V 's Cash & cash equivalent $ 665 Millions Visit MYL's Balance sheet
Source of MYL's Sales Visit MYL's Sales by Geography


Cumulative Mylan N V 's Quick Ratio

MYL's Quick Ratio for the trailling 12 Months

MYL Quick Ratio

 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth 39.59 % 21.31 % 6.54 % -9.85 % -21.57 %
Y / Y Cash & cash equivalent TTM Growth 74.63 % 38.39 % 18.61 % -14.34 % -17.42 %
Quick Ratio TTM 0.08 0.08 0.08 0.07 0.07
Total Ranking TTM # 4694 # 4593 # 4591 # 4597 # 4701
Seq. Current Liabilities TTM Growth 11.73 % 12.04 % 5.65 % 5.55 % -2.9 %
Seq. Cash & cash equivalent TTM Growth 17.27 % 6.76 % 26.06 % 10.65 % -7.06 %

Quick ratio ranking by company, industry and sector >> Back to MYL Financial Strength Comparisons >> Go to Compare MYL Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q3 2020 to $7,275.40 millions, cumulative Quick Ratio remained unchanged at 0.08 below the Mylan N V average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 488 other companies have achieved higher Quick Ratio than Mylan N V . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2020 from 4593 to 4694.

Explain Quick Ratio?
How much Cash & cash equivalents MYL´s has?
What are MYL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 489
Healthcare Sector # 940
Within the Market # 4694


trailing twelve months Quick Ratio Statistics
High Average Low
3.33 0.55 0.05
(Sep. 30, 2005)   (March 31, 2015)




Companies with similar Quick Ratio in the quarter ending Sep 30 2020, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2020 MRQ Cash & cash equivalentSep 30 2020 MRQ Current Liabilities
Cytodyn inc   0.24 $ 18.200  Millions$ 76.424  Millions
Ani Pharmaceuticals Inc  0.24 $ 17.900  Millions$ 75.900  Millions
Serina Therapeutics Inc   0.23 $ 1.107  Millions$ 4.854  Millions
Medicure Inc   0.22 $ 2.080  Millions$ 9.430  Millions
Iterum Therapeutics Plc  0.21 $ 8.570  Millions$ 40.792  Millions
Emmaus Life Sciences Inc   0.21 $ 4.949  Millions$ 23.780  Millions
Enveric Biosciences Inc   0.20 $ 2.840  Millions$ 13.993  Millions
Prestige Consumer Healthcare Inc   0.20 $ 26.603  Millions$ 136.120  Millions
Lftd Partners Inc   0.19 $ 0.158  Millions$ 0.815  Millions
Neos Therapeutics Inc   0.19 $ 12.744  Millions$ 67.161  Millions
Ainos Inc   0.19 $ 0.084  Millions$ 0.445  Millions
Bespoke Extracts Inc  0.19 $ 0.127  Millions$ 0.680  Millions
Health right Discoveries Inc   0.18 $ 1.769  Millions$ 9.979  Millions
Oncotelic Therapeutics Inc   0.16 $ 1.362  Millions$ 8.764  Millions
Teva Pharmaceutical Industries Limited  0.15 $ 1,827.000  Millions$ 12,103.000  Millions
Gsk Plc  0.14 $ 8,596.130  Millions$ 61,966.733  Millions
Reshape Lifesciences Inc  0.14 $ 1.857  Millions$ 13.576  Millions
Mallinckrodt Plc  0.13 $ 844.200  Millions$ 6,503.800  Millions
Processa Pharmaceuticals Inc   0.12 $ 0.325  Millions$ 2.658  Millions
Intellipharmaceutics International Inc   0.12 $ 0.799  Millions$ 6.702  Millions
Scopus Biopharma Inc   0.11 $ 0.421  Millions$ 3.789  Millions
Nascent Biotech Inc   0.11 $ 0.099  Millions$ 0.910  Millions
Opko Health Inc   0.11 $ 36.294  Millions$ 335.889  Millions
Mylan N v   0.09 $ 664.500  Millions$ 7,275.400  Millions
Vincerx Pharma Inc   0.09 $ 0.036  Millions$ 0.402  Millions
One World Products Inc   0.09 $ 0.092  Millions$ 1.035  Millions
Inhibitor Therapeutics Inc   0.08 $ 0.037  Millions$ 0.459  Millions
Zevra Therapeutics Inc   0.07 $ 5.267  Millions$ 70.480  Millions
Jaguar Health Inc   0.05 $ 1.349  Millions$ 25.768  Millions
China Pharma Holdings Inc  0.04 $ 0.347  Millions$ 7.996  Millions

Date modified: 2026-09-26T06:50:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.